SCHEMBL20057532

SCHEMBL20057532

CNC(=O)Nc1ccc(NC(=N)N)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
KMT2A Q03164 3/20 0.58
POLB P06746 2/20 0.49
RAB9A P51151 3/20 0.47
MAPT P10636 2/20 0.47
F2 P00734 1/20 0.46
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
TMPRSS6 Q8IU80 1/20 0.46
ST14 Q9Y5Y6 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
RECQL P46063 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 2/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
PIP4K2A P48426 1/20 0.41
PIP4K2B P78356 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20057642 0.85 DDX3X (0.49) ALDH1A1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL10155599 0.85 ALDH1A1 (0.78) ALDH1A1KMT2APOLBRAB9AMAPT
SCHEMBL18902556 0.83 ALDH1A1 (0.64) ALDH1A1KMT2APOLBRAB9AMAPT
SCHEMBL8686673 0.80 ALDH1A1 (0.68) ALDH1A1KMT2APOLBRAB9AMAPT
SCHEMBL1996992 0.80 F2 (0.50) ALDH1A1RAB9AMAPTF2PRSS1
SCHEMBL10895758 0.79 SMN1; SMN2 (0.61) ALDH1A1KMT2APOLBRAB9AMAPT
SCHEMBL7298885 0.79 MAPT (0.75) ALDH1A1KMT2APOLBRAB9AMAPT
SCHEMBL11773021 0.79 ALDH1A1 (0.64) ALDH1A1KMT2APOLBRAB9AMAPT
SCHEMBL15616276 0.79 ALDH1A1 (0.64) ALDH1A1KMT2APOLBRAB9AMAPT
SCHEMBL11760586 0.79 PEPD (0.64) ALDH1A1KMT2ARAB9AMAPTF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 US disclosed
EP-3309146-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF University of Tsukuba (JP) 2018-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 ALDH1A1 968/4885KMT2A 234/4885POLB 4789/4885
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof HCRTR2, HCRTR1, NPSR1 ALDH1A1 968/4885KMT2A 234/4885POLB 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.